- Home
- DAVA vs MDXG Comparison
DAVA vs MDXG Comparison
Compare DAVA & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAVA
- MDXG
- Stock Information
- Founded
- DAVA 2000
- MDXG 2006
- Country
- DAVA United Kingdom
- MDXG United States
- Employees
- DAVA N/A
- MDXG N/A
- Industry
- DAVA EDP Services
- MDXG Biotechnology: Pharmaceutical Preparations
- Sector
- DAVA Technology
- MDXG Health Care
- Exchange
- DAVA Nasdaq
- MDXG Nasdaq
- Market Cap
- DAVA 885.9M
- MDXG 877.4M
- IPO Year
- DAVA 2018
- MDXG N/A
- Fundamental
- Price
- DAVA $14.94
- MDXG $6.77
- Analyst Decision
- DAVA Buy
- MDXG Strong Buy
- Analyst Count
- DAVA 9
- MDXG 2
- Target Price
- DAVA $25.33
- MDXG $11.50
- AVG Volume (30 Days)
- DAVA 690.5K
- MDXG 963.4K
- Earning Date
- DAVA 09-18-2025
- MDXG 07-30-2025
- Dividend Yield
- DAVA N/A
- MDXG N/A
- EPS Growth
- DAVA N/A
- MDXG N/A
- EPS
- DAVA 0.40
- MDXG 0.27
- Revenue
- DAVA $1,007,631,882.00
- MDXG $352,375,000.00
- Revenue This Year
- DAVA $6.33
- MDXG $9.55
- Revenue Next Year
- DAVA N/A
- MDXG $11.43
- P/E Ratio
- DAVA $37.59
- MDXG $25.08
- Revenue Growth
- DAVA 5.95
- MDXG 5.34
- 52 Week Low
- DAVA $13.12
- MDXG $5.47
- 52 Week High
- DAVA $34.94
- MDXG $10.14
- Technical
- Relative Strength Index (RSI)
- DAVA 52.68
- MDXG 54.91
- Support Level
- DAVA $13.30
- MDXG $6.37
- Resistance Level
- DAVA $15.20
- MDXG $6.99
- Average True Range (ATR)
- DAVA 0.59
- MDXG 0.33
- MACD
- DAVA 0.17
- MDXG 0.03
- Stochastic Oscillator
- DAVA 81.39
- MDXG 73.33
About DAVA Endava plc (each representing one)
Endava is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2006 in the UK and it continues to generate the majority of revenue in the UK and Europe. Endava's client base is concentrated in the payments and financial services, technology, media, and telecom industries.
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.